Background & Aim: Nowadays, the use of herbal products as supplementary or substitute chemical drugs in the treatment of diseases has been associated with low side effects and cost of treatment. The aim of this study was to evaluate the effect of cinnamon aqueous extract on anxiety-like behavior of streptozotocin-induced diabetic male rats.

Methods: In this experimental study, 28 male Wistar rats weighing approximately 200±30 g were used in four groups of seven. For induction of diabetes mice, intraperitoneal injection of 50 mg / kg streptozotocin was used. The experiments were designed for 3 weeks. During this period, the treatment was performed by cinnamon extract at a concentration of 200 mg / kg orally. At the end, recording and evaluation of the anxiety behavior evaluation indicators of mice including duration of presence and The number of access times in the open arms is performed at a set time interval for a period of 5 minutes with a plus maze device. Data were analyzed by one-way ANOVA and Tukey's post hoc test.

Results: There was no significant difference in the duration of presence in the open arms of the elevated plus maze (EPM) between healthy rats receiving cinnamon extract. Also, the results showed that the duration of presence in the open arms of the maze in the control rats Diabetic and diabetic recipients of cinnamon extract were significantly less than healthy ones. The results showed that the duration of presence in the open arms of maze in diabetic control and diabetic rats receiving cinnamon extract was significantly lower from healthy groups (controls and recipients of cinnamon extract). In general, increased anxiety behaviors in diabetic rats Indicates anxiety levels in diabetic rats treated with a small extract compared to diabetic control group, but this is not statistically significant (P≤0.05).

Conclusion: Cinnamon extract has no effect on anxiety and anxiety-like behaviors due to decreased blood glucose. Therefore, it can be suggested that on the one hand, the concentration of cinnamon used to treat diabetic rats is not sufficient to reduce blood glucose and has no effect on the performance of anesthetic neurotransmitter systems.